1. People's Republic of China Stocks

  2. •

    Healthcare

  3. •

    Medical - Devices
Peijia Medical Limited

Peijia Medical Limited

9996.HK
Peijia Medical LimitedHK flagHong Kong Stock Exchange
4.10
HKD
+0.07
- -
2.74BMarket Cap
Peijia Medical Limited
9996.HK
(Hong Kong Stock Exchange)

Recent

price

4.10

P/E

ratio

- -

div

yld

- -

ROIC.AI

2018
2019
2020
2021
2022
2023
2024
2025
FRC
- -
0.03
0.08
0.21
0.37
0.65
0.92
- -
Revenue per Share
-0.14
-0.87
-4.43
-0.87
-0.61
-0.58
-0.34
- -
Basic EPS, GAAP
-0.08
-0.19
-0.45
-0.96
-0.86
-1.39
-0.43
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-0.23
-1.1
-5.85
-4.99
-5.51
-6.04
-6.47
- -
Book Value per Share
-0.16
-1.28
5.53
4.04
3.09
2.51
2.01
- -
Tangible Book Value per Share
610
610
467
662
673
679
669
- -
Basic Weighted Avg Shares
- -
19
39
137
251
441
615
713
Sales/Revenue/Turnover
- -
-1,189.21
-541.37
-402.54
-219.96
-94.27
-37.42
-27.4
Operating Margin (%)
5
13
19
27
36
43
59
68
Depreciation Expense
-83
-532
-2,069
-574
-408
-393
-227
-203
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
-2,844.95
-5,351.59
-420.57
-162.58
-88.98
-36.81
-28.52
Profit Margin (%)
96
507
2,500
2,308
1,429
1,083
544
143
Working Capital
1
1
- -
4
73
205
162
41
LT Debt
-94
-558
2,813
3,019
2,638
2,274
2,045
1,858
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-7.66%
-9.12%
Free Cash Flow
- -
40.73%
14.02%
Net Income, GAAP
- -
-31.51%
-10.28%
Sales/Revenue/Turnover
- -
93.63%
15.82%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
441
2024
- -
- -
- -
- -
615
2025
- -
- -
- -
- -
713

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
-0.58
2024
- -
- -
- -
- -
-0.34
2025
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Similar Companies
Modulight Oyj (MODU.HE)
Beijing Chunlizhengda Medical Instruments Co., Ltd. (688236.SS)
Nureca Limited (NURECA.NS)
INVO Fertility, Inc. (IVF)
Lifeward Ltd. (LFWD)
Bone Biologics Corporation (BBLG)
Business
Peijia Medical Limited (9996.HK) is a leading Chinese developer, manufacturer and seller of interventional medical devices for structural heart and neurovascular diseases. Founded in 2012 and headquartered in Suzhou, Jiangsu Province, China, the company operates primarily in China with manufacturing facilities in Suzhou and Shanghai, and pursues global expansion through strategic partnerships and clinical trials. It focuses on high-growth segments including transcatheter valve therapeutics and neurointerventional procedural solutions; core products encompass transcatheter aortic valve replacement (TAVR) systems such as TaurusOne, TaurusElite, TaurusMax and crosslinked dry-tissue/polymeric tri-leaflet variants; mitral and tricuspid valve devices including GeminiOne transcatheter edge-to-edge repair (TEER) and HighLife transseptal mitral valve replacement (TSMVR); neurointerventional devices comprising hemorrhagic products like flow-diverting stents (YonFlow), balloon dilatation catheters (SacSpeed, Fastunnel), coils; ischemic products including DCwire micro guidewires; and access devices; the company also offers procedural solutions for aortic regurgitation (AR), stenosis (AS) and next-generation technologies such as robotic-assisted TAVR (ReachTactile) and lithotripsy valvuloplasty. In recent developments, Peijia Medical announced 2025 interim results showing revenue of RMB353.4 million, up 17.3% year-over-year, with TAVR products up 24% and neurointerventional up 12.2%; its transcatheter valve therapeutic business achieved first-ever commercial profit of RMB29.1 million; the NMPA approved YonFlow flow-diverting stent in April 2025 with first commercial implant in June 2025 and listings in over 20 provinces; pivotal trials advanced for TaurusTrio AR TAVR (registration accepted April 2025), TaurusNXT durability-enhanced AS TAVR and GeminiOne mitral TEER (registrations pending late 2025-mid 2026); DCwire micro guidewire filed for U.S. FDA 510(k) in July 2025; the company entered a strategic innovation partnership with dsm-firmenich in 2025 for polymer heart valve materials including ultra-high molecular weight polyethylene and thermoplastic polyurethane; and it expanded hospital coverage to over 720 institutions with TAVR implant volume exceeding 2,050 units in H1 2025.

Company News

APIChatGPT

  • prnewswire.com

    Peijia Medical Submits EU MDR CE Mark Registration Application for GeminiOne® TEER System